Introduction
Oncology Grand Rounds represents an invaluable platform for our fellows to learn from faculty and guest lecturers who are thought-leaders in their fields sharing cutting edge clinical and translational research related to medical oncology, malignant hematology, bone marrow transplantation and cellular therapies
Medical Oncology Grand Rounds begin each year after completion of the Friday Introduction to Cancer Management lectures. Fellows and faculty members give 30- to 60-minute, case-based discussions and literature reviews on subjects of their choosing that often include literature reviews, case-based discussions and their own basic and clinical research successes.
Schedule
- Friday, Noon-1:00 PM
- 11th Floor Mid Campus Center, Main Conference Room (in person)
- Zoom (virtual)
Note: Beginning in July, 2016, Hematology Grand Rounds and Medical Oncology Grand Rounds have been held separately.
Academic year
| Date | Speaker | Title |
|---|---|---|
| Sep 6, 2024 | Katharina Sahm | A long peptide vaccine targeting the clonal diver mutation H3K27M in diffuse midline gliomas |
| Sep 13, 2024 | Leo Mascarenhas | Rhabdomyosarcoma in children, adolescents and young adults: What should the standard of care be? |
| Sep 20, 2024 | Yi Wang | Decoding the Intestinal Epithelium in Injury, Regeneration and Malnutrition |
| Sep 27, 2024 | Hughes de The | AML Therapy response requires PML |
| Oct 4, 2024 | Anya Plutynski | Theories, Models, and Theory Change in Cancer Research: A Long View From the History & Philosophy of Science |
| Oct 11, 2024 | Meagan Jacoby | Clearance of Leukemia Associated Mutations is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of the ClinSeq Trial |
| Oct 18, 2024 | Lee Ratner | Molecular Biology of HTLV-1 and Potential Therapeutic Implications in Adult T-cell Leukemia/Lymphoma |
| Oct 25, 2024 | Lian Kim | Development of novel KRAS/MAPK inhibitor-based therapeutic combinations in pancreatic cancer |
| Nov 1, 2024 | Gregory Riely | Failure and Success in Targeted Therapy for Lung Cancer |
| Nov 8, 2024 | Dan Link | TP53 Mutated Myeloid Malignancies |
| Nov 15, 2024 | Urvi Shah (K12 Scholar Exchange) | A High Fiber Dietary Intervention Trial to Delay Progression to Myeloma |
| Nov 22, 2024 | Christine Auberle | Asparagine to Arginine: Unraveling Metabolomics in Lung Cancer |
| Dec 13, 2024 | Francesca Ferraro | Extramedullary AML: A Fresh Look at Old Challenges |
| Dec 20, 2024 | Dineo Khabele (WU OB/GYN) | A Surgeon-Scientist’s Perspective on Ovarian Cancer Care and Research |
| Jan 3, 2025 | ||
| Jan 10, 2025 | Wilbur Song | Targeting Tumor Innate Inflammation in GI Cancers |
| Jan 17, 2025 | ||
| Jan 24, 2025 | Brendan Knapp | |
| Jan 31, 2025 | ||
| Feb 7, 2025 | Imrah Nizamuddin | |
| Feb 14, 2025 | Targeting MET in NSCLC | |
| Feb 21, 2025 | Steven Oh | |
| Feb 28, 2025 | Jacqueline Payton | |
| Apr 11, 2025 | Jesse Zaretsky | |
| Apr 18, 2025 | Kalem Quant | |
| Apr 25, 2025 | Christine Auberle | |
| May 2, 2025 | Jennifer Diaz | |
| May 9, 2025 | Michael Bern | |
| May 16, 2025 | Andrew Aguirre | |
| May 23, 2025 | Kandice Roberts | |
| Jun 6, 2025 | Arun Cumpbelik | |
| Jun 13, 2025 | Hunter Cochran | |
| Jun 20, 2025 | Susrutha Nanrayana | |
| Jun 27, 2025 | Veronica Guerra |
| Date | Speaker | Title |
|---|---|---|
| Jul 7, 2023 | Michael Kramer | Nucleophosmin Mutations in AML: From the Cell to the Patient |
| Sep 8, 2023 | Nathan Singh | Detangling CAR-driven T-cell dysfunction |
| Sep 15, 2023 | Joshua Mitchell | Treating the Cancer While Safeguarding the Heart: Seeking Balance from Prevention through Survivorship |
| Sep 22, 2023 | Amanda Cashen | Human Subjects Research in Oncology: Lessons from a Former IRB Executive Chair |
| Sep 29, 2023 | Neha Mehta-Shah | Taking Steps Towards Progress in Peripheral T-cell Lymphoma |
| Oct 6, 2023 | Piro Lito | Emerging KRAS Directed Therapeutics: Implications for Cancer Biology and Therapy |
| Oct 13, 2023 | Max Wattenberg | Programming the Myeloid Response for Cancer Immunotherapy |
| Oct 20, 2023 | Michael Slade | The Goldilocks Principle: Moving Toward Personalized Maintenance in Multiple Myeloma |
| Oct 27, 2023 | Ron Germain | Using Advanced Multiplex Microscopy and Computational Tools to Analyze Immune Responses in Normal and Malignant Tissues |
| Nov 17, 2023 | Chris Counter | RAS mutation tropism -why specific RAS mutations track with specific cancers |
| Dec 1, 2023 | Bob Maki | Ewing Sarcoma: 100+ years of clinical and scientific progress |
| Dec 15, 2023 | Brian Van Tine | Translating Arginine Deprivation with PEGylated Arginine Deiminase (ADI-PEG 20) in Sarcoma and Other Cancers |
| Jan 5, 2024 | Nathan Singh | Detangling CAR-driven T-cell dysfunction |
| Jan 12, 2024 | CANCELED | |
| Jan 19, 2024 | Imran Nizamuddin | Moving the Goalpost in Post-Transplant Lymphoproliferative Disorders: Current Treatments and Future Directions |
| Jan 26, 2024 | Funda Meric-Bernstam | |
| Feb 2, 2024 | Ramon Jin | |
| Feb 9, 2024 | Greg Longmore | Tumour-Environmental Interactions Regulating Cancer Progression |
| Feb 16, 2024 | Emily Podany | Biomarker-Directed Neoadjuvant Treatment Decisions in HR+/HER2- Breast Cancer and Impacts on Equity |
| Feb 23, 2024 | Russel Pachynski | Improving Cellular Therapy and Diagnosis for Metastatic Prostate Cancer Patients |
| Mar 1, 2024 | Giulia Petrone | The Landscape of Clonal Hematopoiesis in the Era of Precision Medicine |
| Mar 8, 2024 | Patricia LoRusso | Optimal Dose Determination in Phase I Clinical Trials |
| Mar 15, 2024 | Wilbur Song | Pearls & Pitfalls of Targeting Tumor Antigens |
| Mar 22, 2024 | Constantine Logothetis | Inflammation in MDS and VEXAS Syndrome: Does One Size Fit All |
| Mar 29, 2024 | Brendan Knapp | Improving Survival in Unresectable Stage II Non-Small Cell Lung Cancer: Moving Beyond PACIFIC |
| Apr 5, 2024 | Michael Iglesia | Cancer Multiomics: Applications and Updates |
| Apr 12, 2024 | Margaret Ship | Genetic Heterogeneity and Rational Treatment Targets in Lymphoid Malignancies |
| Apr 19, 2024 | Miriam Kim | Investigating the Interactions of CAR-T Cells and Immune Cells |
| Apr 26, 2024 | Nicole Foley | Novel & Emerging Therapies in Cutaneous T-cell Lymphomas |
| May 3, 2024 | Jesse Zaretsky | Chasing Tumor-Specific T-cells in Solid Tumors |
| May 10, 2024 | Tanner Johanns | Antigen Discovery for Immunotherapy Development in Glioblastoma |
| May 17, 2024 | Michael Kramer | Towards the Identification of Druggable Targets for AML Patients with DNMT3A and NPM1 Mutations |
| May 24, 2024 | Nikolaos Trikalinos | A Review of Treatment Strategies for Patients with Neuroendocrine Neoplasms |
| Jun 14, 2024 | Doug Adkins | Head and Neck Cancer Investigator-Initiated Trials |
| Jun 21, 2024 | Michael Bern | Primary-Refractory Acute Myeloid Leukemia: Identifying Mechanisms of Chemoresistance |
| Jun 28, 2024 | Christine Auberle | Beyond Boundaries: New Horizons in Phase I Studies in Oncology |
| Date | Speaker | Title |
|---|---|---|
| Sep 16, 2022 | Andrew Chow | Mobilizing the Full Immunological Armamentarium in Lung Cancer |
| Sep 23, 2022 | Jeffrey Aldrich | Highlights From Research in Supportive Care and Outcome Disparities in Breast Cancer |
| Oct 14, 2022 EPNEC Seminar Room A | Trever Bivona, MD, PhD University of California San Francisco | Emerging Insights Into Oncogenic RTK-RAS Signaling |
| Oct 28, 2022 | Stefan Tarnawsky | Update to the Prognostication and Classification of Myelodysplastic Syndromes |
| Nov 4, 2022 | Mohammad Atiq, MD National Institutes of Health | Exploring Immunocytokine Synergy With Chemotherapy in Metastatic Prostate Cancer |
| Nov 11, 2022 | Katherine Weilbaecher | Breast Cancer Metastasis in Bone: Insights Into Old Therapies and New Approaches |
| Dec 16, 2022 | Maria B. Magella Doyle, MD Department of Surgery | Transplant Oncology – Making New Strides in Cancer Care |
| Jan 6, 2023 | Brad Kahl | Mantle Cell Lymphoma – What Did We Learn in 2022? |
| Jan 13, 2023 | Arvind Ravi, MD, PhD Dana-Farber Cancer Institute | Integrative Approaches to Understanding Therapeutic Response and Resistance |
| Jan 20, 2023 | Thomas Westbrook, MD University of Michigan | Lineage Plasticity in Prostate Cancer: Mechanistic Insight and Therapeutic Implications |
| Jan 27, 2023 | David Russler-Germain | Follicular Lymphoma: New Insights, Treatments, and Opportunities |
| Feb 3, 2023 | Kelly Bolton | Germline Genetic Predisposition to Cancer: Paradigm Shifts and Practical Application in Oncology Care |
| Feb 10, 2023 | Raya Saba | Management of Diffuse Large B-Cell Lymphoma in Older Patients |
| Feb 17, 2023 | Ron Bose | Trastuzumab Deruxtecan in Breast, Lung, and Gastroesophageal Cancers |
| Feb 24, 2023 | Fahrettin Covut | CAR T-Cell and Bispecific Therapies for Relapsed Refractory Multiple Myeloma |
| Mar 3, 2023 | Kian-Huat Lim | Targeting Tumor Innate Inflammation in GI Cancers |
| Mar 10, 2023 | Christopher Maher | Altered Noncoding Regulation Across Solid Tumors |
| Mar 17, 2023 | Priyanka Verma | Targeting Base Damage Repair to Overcome Limitations of PARP Inhibitor Thaerapy in BRCA-Mutant Cancers |
| Mar 24, 2023 Holden Auditorium | Norman “Ned” Sharpless, MD University of North Carolina | Ending Cancer as We Know It: Forecasting Future Cancer Progress |
| Mar 31, 2023 | Akash Patnaik, MD, PhD, MMSc University of Chicago | Activating Innate Immunity in Prostate Cancer: From Bedside to Bench and Back |
| Apr 7, 2023 | Bindiya Patel | Targeting MET in NSCLC |
| Apr 14, 2023 | Andrew Young | Understanding Cancer Risk in Firefighters |
| Apr 21, 2023 | Jonathan Trujillo, MD, PhD University of Chicago | The Role of Cancer Cell-Intrinsic Hypoxia Inducible Factor (HIF) Activation in Tumor Immune Evasion |
| Apr 28, 2023 | Danielle Atibalentja, MD, PhD Stanford University | Deciphering B-Cell Responses in a Pre-Clinical Model of MYC-Driven T-Cell Lymphoma |
| May 5, 2023 | Chongj-Xian Pan, MD, PhD Brigham and Women’s Hospital, Harvard Medical School | Translational Research to Address Unmet Needs in Bladder Cancer |
| May 12, 2023 | Jill Phallen, PhD Johns Hopkins School of Medicine | Liquid Biopsy Approaches and Cell-Free DNA Biology for Early Detection of Cancer |
| May 19, 2023 | Matthew Christopher | Improving the Graft-Versus-AML Effect |
| May 26, 2023 | Jared Cohen | Advances in the Diagnosis and Treatment of Lymphatic Dysgenesis and the Emerging Role of the Medical Oncologist |
| Jun 9, 2023 | Andrea Hagemann, MD Department of Obstetrics & Gynecology | Prioritizing Gynecologic Cancer Prevention: Panel Testing, Preventive Surgeries, and More |
| Jun 16, 2023 | Nicole Foley | Personalizing Therapy for Patients With T-Cell Lymphomas |
| Jun 23, 2023 | Giordano Cittolin-Santos | Small Cell Lung Cancer: Changes in Epidemiology and Recent Advances |
| Jun 30, 2023 | Michael Iglesia Jesse Zaretsky | Liver Metastasis: Seed and Soil Checkpoint Immunotherapy, Beyond Anti-PD1 and CTLA4 |
| Date | Speaker | Title |
|---|---|---|
| Sep 24, 2021 | Whitney Hensing | Targeting HER2 in Breast Cancer: New Drugs and Paradigms |
| Oct 8, 2021 | Rigoberto Pizarro Fahrettin Covut | Overview of Health Disparities in Cancer Minimal Residual Disease in Multiple Myeloma |
| Oct 15, 2021 | Raya Saba Andrew Young | Updates in Frontline Treatment of Chronic Lymphocytic Leukemia Liquid Biopsy for Cancer Screening |
| Oct 22, 2021 | Eric Schwartz | Financial Burdens Surrounding Oral Cancer Therapy |
| Oct 29, 2021 | Patricia Ribeiro Pereira | Non-Invasive Nuclear Imaging of Cancer Biology to Convert Non-Responders Into Responders |
| Nov 5, 2021 | Melissa Reimers | Updates and Recent Advances in Renal Cell Carcinoma |
| Nov 12, 2021 | Daniel Link | Clonal Hematopoiesis: Etiology and Evolution |
| Nov 19, 2021 | Armin Ghobadi | Cellular Therapies for Cancer – A Primer and an Update |
| Nov 26, 2021 | Canceled – Holiday | |
| Dec 3, 2021 | Canceled – ASH Meeting | |
| Dec 10, 2021 | Canceled – ASH Meeting | |
| Dec 17, 2021 | Canceled | |
| Dec 24, 2021 | Canceled – Holiday | |
| Dec 31, 2021 | Canceled – Holiday | |
| Jan 7, 2022 | Patrick White | Innovative Tools and Strategies for Enhancing Support for Your Oncology Patients and Caregivers |
| Jan 14, 2022 | Canceled | |
| Jan 21, 2022 | Matthew Walter | Clonal Evolution of Myelodysplastic Syndromes |
| Jan 28, 2022 | Srivatsan Raghavan | The Tumor Microenvironment Drives Cell State, Plasticity, and Drug Response in Pancreatic Cancer |
| Feb 4, 2022 | Sheila Stewart | Age-Related Stromal Changes Drive Tumor Progression |
| Feb 11, 2022 | Giordano Cittolin-Santos Jared Cohen | Neoadjuvant Immunotherapy in NSCLC The Changing Landscape of Treatment in DLBCL |
| Feb 18, 2022 | Ravi Vij | Multiple Myeloma: The Best Is Yet to Come! |
| Feb 25, 2022 | Joshua Rubin | Adapting Cancer Treatment to Sex Differences in Cancer Biology |
| Mar 4, 2022 | Jason Weber | Identification of Drivers and Vulnerabilities in Breast Cancer |
| Mar 11, 2022 | Jing Wu | Translational Research in Developing a CDK9 Inhibitor Towards a Glioma Treatment |
| Mar 18, 2022 | Canceled | |
| Mar 25, 2022 | Bindiya Patel Michael Kramer | Biomarkers to Guide Adjuvant Therapy in Early-Stage NSCLC The Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia |
| Apr 1, 2022 | Joseph Franses Massachusetts General Hospital | Identifying and Targeting Metastatic and Microenvironmental Drivers in Hepatocellular Carcinoma |
| Apr 8, 2022 | Todd Fehniger | Activate and Recollect: Training Natural Killer Cells for Cancer Immunotherapy |
| Apr 15, 2022 | Jing Xi | A Silent Epidemic? – Disparities in Breast Cancer for Sexual and Gender Minority Women |
| Apr 22, 2022 | Miriam Jacobs | Applications of Memory-Like Natural Killer Cells for Head and Neck Cancer Immunotherapy |
| Apr 29, 2022 | Michael Gillette Broad Institute, Cambridge, MA | Deep Integrated Proteogenomics Reveals New Biology and Therapeutic Vulnerabilities in Non-Small Cell Lung Cancer |
| May 6, 2022 | Foluso Ademuyiwa and Mark Fiala | Racial Disparities in Oncology: Challenges and Opportunities |
| May 13, 2022 | Michael Iglesia | Metastasis in Colorectal Cancer |
| May 20, 2022 | Milan Chheda | Tuning In: A Review of Psychedelics for Patients With Cancer |
| May 27, 2022 | Nicole Foley Michael Slade | T-Cell Lymphomas and HSCT Why CARs Crash: CAR T Cell Treatment Failure and the PD-1/PD-L1 Axis |
| Jun 3, 2022 | Canceled – ASCO Meeting | |
| Jun 10, 2022 | Timothy Ley | AML Proteomics and Interactomics |
| Jun 17, 2022 | Omar Butt | The Intersection of the Blood Brain Barrier, Neuro-Inflammation, and Neuro-Degeneration in Neuro-Oncology |
| Jun 24, 2022 | Charles Swanton Francis Crick Institute, London, UK | PAUL CALABRESI K12 VISITING PROFESSOR Lung Cancer Evolution, Metastases and Immune Evasion: Insights From TRACERx |
| Date | Speaker | Title |
|---|---|---|
| Sep 18, 2020 | Grant Challen | The Epigenetic Regulation of Hematopoietic Stem Cells: From Clonal Hematopoiesis to Myeloid Neoplasia |
| Sep 25, 2020 | Malachi Griffith | Immunogenomics Approaches to Identify and Characterize Neoantigens |
| Oct 9, 2020 | Andrew Young | Clonal Hematopoiesis of Indeterminate and Determinate Potential |
| Oct 16, 2020 | Vanessa Eulo | Advancing Therapies in Sarcoma |
| Oct 30, 2020 | Stephanie Perkins Radiation Oncology Brian Baumann Radiation Oncology | The Role of Proton Therapy in Adult Cancers The Promise of Proton Therapy as Part of Concurrent Chemo-Radiotherapy |
| Nov 6, 2020 | Sid Devarakonda | Implications of Cancer-“omics” Studies for Clinical Practice |
| Nov 13, 2020 | Ryan Fields Department of Surgery | The Clonal Evolution of Metastatic Colon Cancer: Insights and Implications for Patient Care |
| Dec 11, 2020 | Ian Hu, MD, PhD National Cancer Institute | Translational Research at NCI |
| Dec 18, 2020 | Michael Slade Michael Iglesia | Assessing Allogeneic Transplant Eligibility in Older Adults Breast Cancer Subtypes at the Single-Cell Level: Results From the Human Tumor Atlas Network |
| Jan 8, 2021 | Sanjeev Bhalla Department of Radiology | Chest Imaging for the Oncologist |
| Jan 15, 2021 | Fahrettin Covut David Russler-Germain | Advances in Multiple Myeloma Treatment Integrating Genomics Into Lymphoma Treatment Strategies |
| Jan 22, 2021 | Michael Deininger, MD, PhD Huntsman Cancer Institute, University of Utah | A Critical Role for SIRT5 in Acute Myeloid Leukemia Metabolism |
| Jan 29, 2021 | Brian Miller, MD, PhD Harvard Medical School, Dana Farber Cancer Institute | Defining Immune Mechanisms to Overcome Resistance to Immunotherapy |
| Feb 5, 2021 | Amir Iravani Department of Radiology | Molecular Imaging of Cancer and Immune Response to Immunotherapy |
| Feb 12, 2021 | David S. Hong, MD MD Anderson Cancer Center | Cracking Open the Undruggable RAS |
| Feb 19, 2021 | Steven P. Treon, MD, PhD Dana-Farber Cancer Institute | Treatment Advances in Waldenstrom’s Macroglobulinemia |
| Feb 26, 2021 | Whitney Hensing Raya Saba | Targeting HER2 Mutations in Cancer Overview and Advances in Treatment of Mantle Cell Lymphoma |
| Mar 5, 2021 | Priyanka Verma, PhD University of Pennsylvania | Chromatin Accessibility: A New Vulnerability in BRCA-Mutant Cancers |
| Mar 12, 2021 | Dhruv Bansal | Discovering an Immunologic Beachhead in the Prostate Tumor Microenvironment |
| Mar 19, 2021 | Elizabeth M. Jaffee, MD Johns Hopkins University | Pancreatic Cancer Is PRIMED to Become an Immunologic Disease |
| Mar 26, 2021 | Barbara Burtness, MD Yale School of Medicine | The Emerging Therapeutic Landscape in Head and Neck Cancer |
| Apr 2, 2021 | Lindsay Peterson | Precision Nutrition in Cancer Care |
| Apr 9, 2021 | Zahra Kabiri, MD, PhD Duke University | Interrogating the Role of Ras and Wnt Signaling Intensity in Colorectal Cancer |
| Apr 16, 2021 | Robert Orlowski, MD, PhD MD Anderson Cancer Center | Novel Antibody Drug Conjugates for Hematologic Malignancies |
| Apr 23, 2021 | Miriam Jacobs | The Role of Natural Killer Cells in Solid Tumor Immunotherapy |
| Apr 30, 2021 | Ramon Jin | The Role of SOX2 in Barrett’s Esophagus and Esophageal Adenocarcinoma |
| May 7, 2021 | Gradon Nielsen | Impact of COVID on the Quality of Cancer Care Delivery |
| May 14, 2021 | Jing Xi | The Emerging Therapeutic Landscape in Breast Cancer With Brain Metastases |
| May 21, 2021 | Christian Grommes, MD Memorial Sloan Kettering Cancer Center | Primary CNS Lymphoma: Current Concepts and Changing Therapeutic Perspectives |
| May 28, 2021 | Zachary Crees Alice Zhou | The GENESIS Trial – CXCR4 Inhibition With Motaxafortide + G-CSF for Hematopoietic Stem Cell Mobilization in Multiple Myeloma Multiple Myeloma and the Tumor Microenvironment: Focus on NK Cells and Therapeutic Exploitation |
| Jun 11, 2021 | Carmen Bergom, MD, PhD Radiation Oncology | Un-Break My Heart: Using Pre-Clinical and Clinical Data to Minimize Radiation-Induced Heart Dysfunction |
| Jun 18, 2021 | Michael Kramer | Machine Learning for the Oncologist: How the Machines Can Help You Help Patients |
| Jun 25, 2021 | Kelsey S. Lau-Min, MD University of Pennsylvania | Bridging the Evidence-To-Practice Gap in Cancer Care: The Precision Oncology Experience |
| Jul 2, 2021 | Ryan Day | Core-Binding Factor Leukemias: Mechanism and Treatment |
| Date | Speaker | Title |
|---|---|---|
| Aug 9, 2019 | Mark E. Burkard, MD, PhD University of Wisconsin School of Medicine & Public Health, Madison, WI | Enhancing Precision of Breast Cancer Treatment |
| Aug 16, 2019 | Trudy G. Oliver, PhD University of Utah, Salt Lake City, UT | MYC Drives a Unique Metabolic and Therapeutically-Relevant Subset of Small Cell Lung Cancer |
| Sep 13, 2019 | Patrick Grierson | The MK2/Hsp27 Axis as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma |
| Sep 20, 2019 | Julien Sage, PhD Stanford University, Stanford, CA | Mechanisms of Small Cell Lung Cancer Metastasis |
| Sep 27, 2019 | Ramon Jin | Organoids to Study Upper GI Malignancies |
| Oct 4, 2019 | Shivani Ahlawat, MD Johns Hopkins University, Baltimore, MD | Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Tumors – What Is the State of the Art Imaging? |
| Oct 18, 2019 | Gradon Nielsen Alice Zhou | High Value Cancer Care Immunosuppression and Tumorigenesis: Lessons From Cyclosporine A on Angiogenesis |
| Oct 25, 2019 | Keith Stewart, MB, ChB, MBA Mayo Clinic, Rochester, MN | HARVEY & LINDA SALIGMAN LECTURE Multiple Myeloma: Advances in Diagnostics and Care |
| Nov 1, 2019 | Sarat Chandarlapaty, MD, PhD Memorial Sloan Kettering Cancer Center, New York, NY | Breast Cancer Resistance to Combination Endocrine Therapy: Mechanisms and Therapeutic Implications |
| Nov 22, 2019 | Mary-Kate Malecek Zachary Crees | Targeting the PI3K Pathway in Cancer Bone Marrow Niche – Hematopoietic Stem Cell (HSC) Signaling and Therapeutic Implications for Peripheral Blood (PB) HSC Mobilization |
| Dec 13, 2019 | John L. Hays, MD, PhD Ohio State University, Columbus, OH | Finding the Right Targets in Recurrent Ovarian Cancer |
| Dec 20, 2019 | Daniel J. Lenihan, MD Cardiovascular Division | Cardio-Oncology: A New Part of the Team |
| Jan 10, 2020 | Ryan Day Daniel Guy | Maintenance Therapy in AML/MDS Blastic Plasmacytoid Dendritic Cell Neoplasm |
| Jan 17, 2020 | Aadel Chaudhuri Radiation Oncology | Cell Free DNA Liquid Biopsy: Tumor Surveillance, Risk Stratification and MRD Detection |
| Jan 24, 2020 | George Souroullas | Understanding the Role of EZH2 Mutations on Chromatin Dynamics and Oncogenesis |
| Jan 31, 2020 | Brett Herzog | Modeling Stromal-Induced Immunotherapy Resistance in Lung Cancer |
| Feb 7, 2020 | Jason Held | Cancer Biochemistry Through the Lens of Chemical and Redox Biology |
| Feb 14, 2020 | Francesca Ferraro | Measurable Residual Disease (MRD) in AML: Challenges and Opportunities for Intervention |
| Feb 21, 2020 | Alessandro Vindigni | Mechanisms of DNA Replication Stress Response to Chemotherapeutics |
| Feb 28, 2020 | Mia Weiss, MD Rush University Medical Center, Chicago, IL | Treatment of Metastatic Soft Tissue Sarcoma in the Era of Next Generation Sequencing |
| Mar 6, 2020 | Derek A. Wainwright, PhD Northwestern University, Chicago, IL | Improving Survival by Reversing the Effects of Aging in Patients With Glioblastoma |
| Mar 13, 2020 | Conference suspended until May 1 due to COVID-19 | |
| May 1, 2020 | Lauren Shea Jing Xi | Treatment of PTLD: Current Approaches and Emerging Therapies Emerging Novel Therapies for HER2-Positive Metastatic Breast Cancer |
| May 15, 2020 | Bruna Pellini Ferreira | Urinary Cell-Free DNA Analysis for Tumor Mutation Detection in Patients With Oligometastatic Colorectal Cancer |
| May 29, 2020 | Haeseong Park | COVID-19 and Cancer |
| Jun 5, 2020 | Stephen Sykes, PhD Fox Chase Cancer Center, Philadelphia, PA | The Role and Regulation of Serine Metabolism in Acute Myeloid Leukemia |
| Jun 12, 2020 | Michael Iglesia Miriam Jacobs | Predicting Response to Immunotherapy: PD-L1 and Beyond The Role of IL-15 as a Cancer Immunotherapy |
| Jun 19, 2020 | Whitney Hensing David Russler-Germain | Immunotherapy in TNBC: Advances in Early Stage Disease Bispecific Antibodies in Lymphoid Malignancies: Past, Present, and Future |
| Date | Speaker | Title |
|---|---|---|
| Sep 7, 2018 | Melissa A. Reimers, MD University of Michigan, Ann Arbor, MI | Precision Medicine and Immunotherapy in Metastatic Prostate Cancer |
| Sep 14, 2018 | Jonathan R. Strosberg, MD Moffitt Cancer Center, Tampa, FL | Overview of Treatments for Metastatic Gastroenteropancreatic Neuroendocrine Tumors |
| Sep 28, 2018 | Matthew J. Ellis, MD, PhD Baylor College of Medicine, Houston, TX | Breast Cancer Proteogenomics |
| Oct 5, 2018 | Benjamin Tan | Localized Rectal Cancer: Navigating Shifting Paradigms |
| Oct 12, 2018 | Aabha Oza | Management of Advanced Renal Cell Carcinoma |
| Oct 19, 2018 | Armin Ghobadi | CAR-T Cell Therapy and Its Complications |
| Oct 26, 2018 | Nabil M. Ahmed, MD, MPH Baylor College of Medicine, Houston, TX | A Homing System Targets Therapeutic T Cells to Brain Cancer |
| Nov 2, 2018 | Kenneth C. Anderson, MD Dana-Farber Cancer Institute, Boston, MA | Novel Therapeutic Strategies in Multiple Myeloma |
| Nov 9, 2018 | Nkiruka Ezenwajiaku Ramon Jin | Molecular Classification of Triple Negative Breast Cancer GI Organoids in Cancer Research |
| Dec 7, 2018 | Amber Xu | Target Therapy in Non-Small Cell Lung Cancer |
| Dec 14, 2018 | Milan Chheda | Using Zika Virus to Target Glioblastoma Stem Cells |
| Jan 4, 2019 | Kristen Sanfilippo | Cancer Associated Thrombosis: Prevention to Treatment |
| Jan 11, 2019 | Brett Herzog Ramzi Abboud | Fibrosis Modulates Lung Cancer Immunity and Progression Invariant NKT Cells: Harnessing Their Immunoregulatory and Effector Functions |
| Jan 18, 2019 | David DeNardo | Targeting the Pancreas Cancer Tumor Microenvironment to Improve Response to Immunotherapy |
| Jan 25, 2019 | Gradon Nielsen Lauren Shea | Economic Challenges in Modern Oncology and the Need for Innovation Treatment of Brain Metastases in Non-Small Cell Lung Cancer |
| Feb 1, 2019 | Kian Lim | Targeting the Innate Immune Inflammatory Pathway in Pancreatic Cancer |
| Feb 8, 2019 | Bruna Pellini Ferreira Daniel Guy | Urinary cfDNA in Lung Cancer Surveillance: Present and Future Directions Bispecific Antibodies for Treatment of AML |
| Feb 15, 2019 | Meagan Jacoby | Can Measurable Residual Disease Monitoring Post-Transplant Improve Outcomes for MDS Patients? |
| Feb 22, 2019 | James Hsieh | Clinical and Translational Kidney Cancer Research: Now & Future |
| Mar 1, 2019 | Katherine Clifton, MD MD Anderson Cancer Center, Houston, TX | Exploring Oral Therapy Options in Geriatric Oncology: Analysis of Toxicity and Efficacy Of CDK4/6 Inhibitors in Metastatic Breast Cancer |
| Mar 15, 2019 | Sunyoung Lee, MD, PhD Roswell Park Comprehensive Cancer Center, Buffalo, NY | Immune Profiling and Prognostication of Lung and Pancreatic Adenocarcinoma |
| Mar 22, 2019 | Karin Hickey, MD Division of Endocrinology, Metabolism & Lipid Research | Endocrine Disorders in Cancer Patients |
| Mar 29, 2019 | Angela Hirbe | Clinical Challenges in the Diagnosis and Management of Neurofibromatosis-associated MPNSTs |
| Apr 5, 2019 | John Welch | Integrating Next-Generation Sequencing Into AML and MDS Clinical Trials |
| Apr 19, 2019 | Matthew Christopher | AML and the Graft-Versus-Leukemia Effect |
| Apr 26, 2019 | Vanessa Eulo Scott Goldsmith | Immunotherapy in Advanced Sarcoma Unfolding the Unfolded Protein Response: Implications for Cancer Therapy |
| May 3, 2019 | Charles Kaufman | Epigenetic Regulators of Melanoma Initiation |
| May 10, 2019 | David Spencer | Understanding Aberrent DNA Methylation in Leukemia |
| May 17, 2019 | Tanner Johanns | Neoantigens as Therapeutic Targets in Glioblastoma |
| May 24, 2019 | Ryan Day Mary-Kate Malecek | Targeting Apoptosis in AML Novel Therapies in Primary CNS Lymphoma |
| Jun 7, 2019 | Amber Afzal Miriam Jacobs | CDK9 Inhibition in Acute Myeloid Leukemia Use of Cytokine Induced Memory Like NK Cells for Relapsed Refractory AML |
| Jun 14, 2019 | Michael Green, MD MD Anderson Cancer Center, Houston, TX | Epigenetic Targeting of B-Cell Lymphoma |
| Jun 21, 2019 | Obi Griffith | Surveying the Genomic Landscape of Tumors and Tumor Models – The Next Frontier |
| Jun 28, 2019 | Gerald P. Linette, MD, PhD University of Pennsylvania, Philadelphia, PA | Immunological Ignorance of Solid Tumors |
| Date | Speaker | Title |
|---|---|---|
| Aug 25, 2017 | Nusayba Bagegni | Overcoming Drug Resistance in HER2+ Breast Cancer |
| Sep 1, 2017 | Ravi Vij | MM: AK47 or M24 |
| Sep 15, 2017 | Natasha Edwin | Physician Immigration and the US |
| Sep 22, 2017 | Jeffrey S. Miller, MD University of Minnesota | Novel Ways to Activate NK Cells to Treat Cancer |
| Sep 29, 2017 | Emily Jungheim, MD, MSCI Obstetrics and Gynecology | Fertility Preservation in 2017 at Washington University |
| Oct 6, 2017 | Brad Kahl | Mantle Cell Lymphoma: The State of the State |
| Oct 13, 2017 | Craig H. Moskowitz, MD Memorial Sloan Kettering Cancer Center | Hodgkin Lymphoma in the Near Future: Impact of Modern Nuclear Medicine, Radiotherapy, Brentuximab Vedotin and the Checkpoint Inhibitors |
| Oct 20, 2017 | Miriam Jacobs Ramon Jin | Immunotherapy in Metastatic Squamous Cell Head and Neck Cancer Cancer Stem Cells in Solid Tumors |
| Oct 27, 2017 | Bita Fakhri | Current and Emerging Treatment Strategies for Relapsed and Refractory Multiple Myeloma |
| Nov 3, 2017 | Ron Bose | Her2 Activating Mutations and the Challenge of Variants of Unknown Significance (VUS) in Breast Cancer Patients |
| Nov 10, 2017 | Daniel J. Lenihan, MD Cardiovascular Division | Cardio Oncology: How Can We Improve Practice? |
| Nov 17, 2017 | Eric Huselton | Improving Outcomes After Allogeneic Tranplant: Risk Factors and Treatment of Relapsed AML |
| Dec 1, 2017 | Ramzi Abboud Brett Herzog | JAK/STAT Pathways and Immunomodulation After Hematopoietic Cell Transplantation and Other Immune Therapies Clonal Dynamics of Non-Small Cell Lung Cancer |
| Dec 15, 2017 | Doug Adkins | Current Clinical Investigations in Head and Neck Cancer at Washington University |
| Dec 22, 2017 | Vivek Arora | Emerging Concepts in Bladder Cancer Management |
| Jan 5, 2018 | Brian Van Tine | Sarcoma Metabolism |
| Jan 12, 2018 | Neha Mehta-Shah | T-Cell Lymphomas: Where We Are and Where We Hope to Be |
| Jan 19, 2018 | Brigitte C. Widemann, MD Pediatric Oncology Branch, NCI | Development of Effective Therapies for NF1 Related Peripheral Nerve Sheath Tumors |
| Jan 26, 2018 | Daniel Guy Amber Xu | Age-Related Clonal Hematopoiesis Past, Present and Future of PARP Inhibition |
| Feb 2, 2018 | Lawrence Einhorn, MD Indiana University | Testicular Cancer: Past History, Present Results and Future Perspectives |
| Feb 9, 2018 | Bruna Pellini Ferreira Nkiruka Ezenwajiaku | Cell Tumor DNA in the Diagnosis and Follow-Up of NSCLC Mixed Phenotype Acute Leukemia |
| Feb 16, 2018 | John P. Leonard, MD Weill Cornell Medical College | New Developments in Lymphoma: Progress and Problems in Precision Therapy |
| Feb 23, 2018 | David T. Curiel, MD, PhD Radiation Oncology | Molecular Engineering of Adenovirus to Actualize Cancer Vaccines |
| Mar 2, 2018 | Thomas M. Maddox, MD, MSc Cardiovascular Division | The Health Systems Innovation Lab: Opportunities to Think Differently About Cancer Care |
| Mar 9, 2018 | Monte Meier Winslow, PhD Stanford University | Molecular Determinants of Lung Cancer Growth and Metastasis |
| Mar 16, 2018 | Daniel Guy Aabha Oza | Prevention of CMV Infection in Patients Undergoing HSCT Progressive Multifocal Leukoencephaolpathy |
| Mar 30, 2018 | Russell W. Jenkins, MD, PhD Dana-Farber/Harvard Cancer Center | Ex-Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids: Developing a Functional Precision Medicine Platform for Immuno-Oncology |
| Apr 6, 2018 | Ramon Jin Patrick Grierson | Metaplasia: The Calm Before the Storm? Targeting the MAPK Pathway in Solid Tumors |
| Apr 13, 2018 | Lee Ratner | Pathogenesis and Treatment of Human T-Cell Leukemia Virus Associated Malignancy |
| Apr 20, 2018 | John DiPersio | Therapeutic Targeting of Hematologic Malignancies |
| Apr 27, 2018 | Jeff Ward | Remodeling of Intratumoral Myeloid and Lymphoid Compartments Following Immune Checkpoint Blockade Therapy |
| May 18, 2018 | Jeffrey A. Moscow, MD Cancer Therapy Evaluation Program, NCI | Precision Cancer Medicine and the NCI’s Experimental Therapeutics Clinical Trials Network (ETCTN) |
| May 25, 2018 | Russell Pachynski | Chemerin in Cancer |
| Jun 8, 2018 | Matthew A. Ciorba, MD Gastroenterology Division | Save IDO Inhibitors! A Role for Tryptophan Metabolism in Colon Cancer |
| Jun 15, 2018 | Francesca Ferraro Amber Afzal | From MGUS to MGCS: When the “Uncertain” Turns to “Ugly” BCL2 Inhibition in Myeloid Malignancies |
| Jun 22, 2018 | Gad Getz, PhD Harvard Medical School | Studying Response and Resistance to Therapy in Cancer |
| Jun 29, 2018 | Pasi A. Jänne, MD, PhD Harvard Medical School | New Therapeutic Stratgies for EGFR Mutant Lung Cancer |
| Date | Speaker | Title |
|---|---|---|
| Jul 15, 2016 | Doug Adkins | INTRODUCTION TO CANCER MANAGEMENT Writing Chemo Orders: The Basics I Must Know and Implement |
| Jul 2, 2016 | Janelle Mann Staff Pharmacist, Medical Oncology | INTRODUCTION TO CANCER MANAGEMENT The Ins and Outs of Anti-Emetics |
| Jul 29, 2016 | Cynthia Ma | INTRODUCTION TO CANCER MANAGEMENT Metastatic Hormone Positive Breast Cancer |
| Aug 5, 2016 | Daniel Morgensztern | INTRODUCTION TO CANCER MANAGEMENT Non-Small Cell Lung Cancer |
| Aug 12, 2016 | Tanya Wildes | INTRODUCTION TO CANCER MANAGEMENT Head and Neck Cancer |
| Aug 19, 2016 | William D. Tap, MD Memorial Sloan Kettering Cancer Center, New York, NY | The Pit and the Pendulum, Emerging Therapies in Soft Tissue Sarcoma |
| Aug 26, 2016 | Nancy Bartlett | INTRODUCTION TO CANCER MANAGEMENT Hodgkin Lymphoma |
| Sep 2, 2016 | Nancy Bartlett | Targeted Approaches to Diffuse Large B Cell Lymphoma |
| Sep 9, 2016 | Timothy Ley | Acute Myeloid Leukemia |
| Sep 16, 2016 | Todd Fehniger | Natural Killer Cell Immunotherapy: Prime or Recollect? |
| Sep 23, 2016 | Gloria M. Petersen, PhD Mayo Clinic College of Medicine, Rochester, MN | LORI GROETKEN MEMORIAL LECTURE Genetic Susceptibility to Pancreatic Cancer: New Insights |
| Sep 30, 2016 | Todd Druley Pediatric Hematology/Oncology | Leukemia-associated Clonal Hematopoiesis Is a Ubiquitous Process in Normal Aging |
| Oct 7, 2016 | Cynthia Ma | CDK 4/6 in ER+ Breast Cancer |
| Oct 14, 2016 | Lingling Du Hematology-Oncology Fellow | IDO Inhibition in Cancer Treatment |
| Oct 21, 2016 | Gideon M. Blumenthal, MD Center for Drug Evaluation and Research, FDA, Bethesda, MD | Clinical Trials and Drug Development in Oncology: FDA’s Perspective |
| Oct 28, 2016 | Katherine Weilbaecher | Targeting Dormant and Growing Bone Metastases |
| Nov 4, 2016 | Craig Lockhart | Strategic Targeting of Esophageal Cancers: 2016 Update |
| Nov 11, 2016 | Bita Fakhri Hematology-Oncology Fellow Amber Xu Hematology-Oncology Fellow | Livin’ on a Prayer: Double and Triple Hit Lymphomas Paraneoplastic Opsoclonus-Myoclonus Syndrome |
| Nov 18, 2016 | Sana Saif Ur Rehman Hematology-Oncology Fellow | Chronic Neutrophilic Leukemia: Novel Mutations and Impact on Clinical Practice |
| Dec 9, 2016 | Tom Regenbogen Hematology-Oncology Fellow | Non-Surgical Liver Directed Therapy |
| Dec 16, 2016 | Mark Watson Laboratory & Genomic Medicine | Detection of Rare Tumor Cells |
| Jan 6, 2017 | Scott Kopetz, MD, PhD MD Anderson Cancer Center, Houston, TX | Targeting BRAF in Colorectal Cancer |
| Jan 20, 2017 | Francesca Ferraro Hematology-Oncology Fellow Eric Huselton Hematology-Oncology Fellow | Hypomethylating Agents in Acute Myeloid Leukemia BCL-2 Inhibition in CLL |
| Jan 27, 2017 | Marcel van den Brink, MD, PhD Memorial Sloan Kettering Cancer Center, New York, NY | Strategies to Enhance Hematopoietic Stem Cell Transplantation |
| Feb 3, 2017 | Sid Devarakonda Hematology-Oncology Fellow | Origins and Genomic Landscape of Small Cell Lung Cance |
| Feb 10, 2017 | Sam Achilefu Radiology | Light Mediated Molecular Imaging and Treatment of Cancer |
| Feb 17, 2017 | Maria-Grazia Roncarolo, MD Stanford University, Stanford, CA | T Regulatory Cells in Immunomediated Diseases: From Bench to Bedside and Beyond |
| Feb 24, 2017 | Richard Wahl Radiology | Quantitative Imaging to Phenotype Patients With Cancer |
| Mar 3, 2017 | Deborah Schrag, MD, MPH Dana-Farber Cancer Institute, Boston, MA | Pilots to Populations: Quality, Efficacy and Effectiveness of Rectal Cancer Treatment |
| Mar 10, 2017 | Andy Liao Hematology-Oncology Fellow | Emerging Treatment Options in Cholangiocarcinoma |
| Mar 17, 2017 | Amanda Cashen | CAR T-Cells: How Will We Weigh the Risks and Benefits? |
| Mar 24, 2017 | Ezra Cohen, MD UC San Diego, La Jolla, CA | Immune Approaches in Head and Neck Cancer |
| Mar 31, 2017 | Natasha Edwin Hematology-Oncology Fellow Patrick Grierson Hematology-Oncology Fellow | Burnout Among Oncologists Immunotherapy in GI Malignancies |
| Apr 7, 2017 | Aabha Oza Hematology-Oncology Fellow Stephen Barman Hematology-Oncology Fellow | Peritoneal Carcinomatosis: Intraperitoneal Chemotherapy and Cytoreductive Surgery Urothelial Carcinoma: Review and Updates of Second-Line Treatment |
| Apr 14, 2017 | Goutham Narla, MD, PhD Case Western Reserve University, Cleveland, OH | Novel Therapies to Activate Tumor Suppressor Proteins for Cancer Treatment |
| Apr 21, 2017 | Kwok-Kin Wong, MD, PhD NYU Langone Medical Center, New York, NY | The Use of Mouse Lung Cancer Models for Preclinical Testing of Novel Targeted and Immune Therapies |
| Apr 28, 2017 | Vassiliki Saloura, MD University of Chicago | WHSC1L1 as an Oncogenic Methyltransferase in Head and Neck Cancer: Progress Towards Clinical Translation |
| May 5, 2017 | Tanya Wildes | Age Is Just a Surrogate for Aging: Weaving the Principals of Geriatrics Into the Fabric of Oncology |
| May 12, 2017 | Tanner Johanns Hematology-Oncology Fellow | hTERT as an Immunologic Target |
| May 19, 2017 | Nusayba Bagegni Hematology-Oncology Fellow Francesca Ferraro Hematology-Oncology Fellow | Management of Leptomeningeal Disease Secondary ALL (Acute Lymphoblastic Leukemia): A Real Entity? |
| May 26, 2017 | Nkiruka Ezenwajiaku Hematology-Oncology Fellow Amber Afzal Hematology-Oncology Fellow | Hepatic Veno-Occlusive Disease Outcomes of Stem Cell Transplant in Myelofibrosis |
| Jun 9, 2017 | Patrick Grierson Hematology-Oncology Fellow Pavan Bhamidipati Hematology-Oncology Fellow | NK Cell Lymphoma IDH Mutations in AML and Novel Therapeutics |
| Jun 16, 2017 | Chris Maher | The Biological and Clinical Significance of Long Non-Coding RNAs |
| Jun 23, 2017 | Matt Walter | Genomics of Myelodysplastic Syndromes |
| Jun 30, 2017 | F. Stephen Hodi, MD Dana-Farber Cancer Institute, Boston, MA | Combinatorial Approaches With Immune Checkpoint Blockade to Treat Cancer |